Zoetis has signed a definitive agreement with Phibro Animal Health under which Phibro will acquire the company’s medicated feed additive (MFA) product portfolio, some water-soluble products & related assets for an aggregate of $350M. The transaction is anticipated to conclude in H2’24
The acquisition covers >37 product lines from the portfolio along with 6 manufacturing sites incl. 4 in the US and 1 in Italy & China
Through this divestment, Zoetis will be able to utilize its livestock investments for developing other solutions such as vaccine, biologic & genetic programs
Ref: Zoetis | Image: Zoetis
Related News:- Zoetis’ Librela (bedinvetmab) Receives the US FDA’s Approval to Control Osteoarthritis Pain in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
